

43. Gale NW, Kaplan S, Lowenstein EJ, et al. Grb2 mediates EGF-c dependent activation of guanine nucleotide exchange on Ras. *Nature* 1993; 363: 88-92
44. Chardin P, Camonis JH, Gale N, et al. Human Sos1: a guanine nucleotide exchange factor for Ras that binds to GRB2. *Science* 1993; 260: 1338-43
45. Rozakis-Adcock M, Fernley R, Wade J, et al. The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator mSos1. *Nature* 1993; 363: 83-5
46. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. *Science* 1990; 247: 824-30
47. Diekmann D, Brill S, Garrett MD, et al. Bcr encodes a GTPase activating protein for p21ras. *Nature* 1991; 351: 400-2
48. Mandanas RA, Leibowitz DS, Gharehbaghi K, et al. Role in p21 RAS in p210 bcr-abl transformation of murine myeloid cells. *Blood* 1993; 82: 1838-47
49. Khosvari-Far R, Cox AD, Kato K, et al. Protein prenylation: key to ras function and cancer intervention? *Cell Growth Differ* 1992; 3: 461-9
50. James GL, Goldstein JL, Brown MS, et al. Benzodiazepine peptidomimetics: potent inhibitors of ras farnesylation in animal cells. *Science* 1993; 260: 1937-42
51. Kohl NE, Mosser SD, deSolms SJ, et al. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. *Science* 1993; 260: 1934-7
52. Bonner TI, Kerby SB, Sutrave P, et al. Structure and biological activity of human homologs of the raf/nil oncogene. *Mol Cell Biol* 1985; 5: 1400-7
53. Stokoe D, Macdonald SG, Cadwallader K, et al. Activation of Raf as a result of recruitment to the plasma membrane. *Science* 1994; 264: 1463-7
54. Leever SJ, Paterson HF, Marshall CJ. Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. *Nature* 1994; 369: 411-4
55. Greenblatt MS, Bennett WP, Hollstein BM, et al. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. *Cancer Res* 1994; 54: 4855-78
56. Barlow DP. Methylation and imprinting: from host defense to gene regulation. *Science* 1993; 260: 309-10
57. Hartwell LH, Kastan MB. Cell cycle control and cancer. *Science* 1994; 266: 1821-8
58. Oliner JD, Pietenpol JA, Thiagalingam S, et al. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. *Nature* 1993; 362: 857-60
59. Hancock SL, Tucker MA, Hoppe RT. Breast cancer after treatment Hodgkin's disease. *J Natl Cancer Inst* 1993; 85: 25-31
60. Gaidano G, Ballerini P, Gong JZ, et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. *Proc Natl Acad Sci USA* 1991; 88: 5413-7
61. Thut CJ, Chen JL, Klemm R, et al. p53 transcriptional activation mediated by coactivators TAF<sub>II</sub>40 and TAF<sub>II</sub>60. *Science* 1995; 267: 100-4
62. Wang CY, Petryniak B, Thompson CB, et al. Regulation of the Ets-related transcription factor E1f-1 by binding to the retinoblastoma protein. *Science* 1993; 260: 1330-5
63. Hendry LB, Muldoon TG. Actions of an endogenous anti-tumorigenic agent on mammary tumor development and modeling analysis of its capacity for interacting with DNA. *J Steroid Biochem* 1988; 30: 325-8
64. Scheffner M, Werness BA, Huibregtse JM, et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. *Cell* 1990; 63: 1129-36
65. Liang XH, Volkmann M, Klein R, et al. Co-localization of the tumor-suppressor protein p53 and human papilloma-virus E6 protein in human cervical carcinoma cell lines. *Oncogene* 1993; 8: 2645-52
66. Speir E, Modali R, Huang ES, et al. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. *Science* 1994; 265: 391-4
67. Benditt EP, Benditt JM. Evidence for a monoclonal origin of human atherosclerotic plaques. *Proc Natl Acad Sci USA* 1973; 70: 1753-6
68. Ballester R, Marchuk D, Boguski M, et al. The NFI locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. *Cell* 1990; 63: 851-9
69. Martin GA, Viskochil D, Bollag G, et al. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. *Cell* 1990; 63: 843-9
70. Bandara LR, Adamczewski JP, Hunt T, et al. Cyclin A and the retinoblastoma gene product complex with a common transcription factor. *Nature* 1991; 352: 249-51
71. Mannevik B, Alin P, Guthenberg C, et al. Identification of three classes of cytosolic glutathione transferase common to several mammalian species: correlation between structural data and enzymatic properties. *Proc Natl Acad Sci USA* 1985; 82: 7202-6
72. Meyer DJ, Coles B, Pemble SE, et al. Theta, a new class of glutathione transferases purified from rat and man. *Biochem J* 1991; 274: 409-14
73. Nazar-Stewart V, Motulsky AG, Eaton DL, et al. The glutathione S-transferase mu polymorphism as a marker for susceptibility to lung carcinoma. *Cancer Res* 1993; 53: 2313-8
74. Bell DA, Taylor JA, Paulson DF, et al. Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. *J Natl Cancer Inst* 1993; 85: 1159-64
75. Lafuente A, Pujol F, Caretero P, et al. Human glutathione S-transferase mu (GST $\mu$ ) deficiency as a marker for the susceptibility to bladder and larynx cancer among smokers. *Cancer Lett* 1993; 68: 49-54
76. Fryer AA, Zhao L, Alldersea J, et al. The glutathione S-transferases: polymerase chain reaction studies on the frequency of the GSTM1 0 genotype in patients with pituitary adenomas. *Carcinogenesis* 1993; 14: 563-6
77. Burzynski SR. Treatment of bladder cancer with antineoplaston formulations. *Adv Exp Clin Chemother* 1988; 2: 37-46
78. Lee SS, Mohabbat MO, Burzynski SR. Tissue culture and acute animal toxicity studies of antineoplaston A2. *Future Trends Chemother* 1985; 6: 481-4
79. Lee SS, Mohabbat MO, Burzynski SR. In vitro cancer growth inhibition and animal toxicity studies of antineoplaston A3. *Drugs Exp Clin Res* 1987; 13 Suppl. 1: 13-6
80. Lee SS, Burzynski SR. Tissue culture and animal toxicity studies of antineoplaston A5. *Drugs Exp Clin Res* 1987; 13 Suppl. 1: 31-5
81. Khalid M, Burzynski SR. N,N' disubstituted L-isoglutamines as novel cancer chemotherapeutic agents. *Drugs Exp Clin Res* 1987; 13 Suppl. 1: 57-60
82. Muldoon TG, Copland JA, Lehner AF, et al. Inhibition of spontaneous mouse mammary tumour development by antineoplaston A10. *Drugs Exp Clin Res* 1987; 13 Suppl. 1: 83-8
83. Muldoon TG, Copland JA, Hendry LB. Actions of antineoplaston A10 on the genesis and maintenance of specific sub-population of rodent mammary tumor cells. *Adv Exp Clin Chemother* 1988; 2: 15-8